Regenerative medicine is a fast-moving, interdisciplinary field, looking for ways to repair or replace parts of the body that are diseased or damaged. Now there’s an established and growing UK research community, we’re changing the way we fund this type of research. Two researchers explain why our continued support for this field – from the early discovery stage to translation into the clinic – will help deliver life-changing treatments for currently incurable conditions.
Adult stem cells from the tissue lining the human knee joint, grown in a dish. These cells can repair
damaged cartilage and are being trialled in the clinic. Individual stem cells are labelled with different fluorescent colours. Image credit: Nathan White, University of Aberdeen.
In her commended 2016 Max Perutz Science Writing Award article, PhD student Edie Crosse, from the MRC Centre for Regenerative Medicine, describes her research aiming to generate healthy stem cells from patients to treat leukaemia.
Blood, both vital and sinister, is tied so closely to our ideas of what it is to be human, warm and alive.
Throughout history people have felt connected to their families, tribes and countrymen imagining that the same blood flows through their veins – as if more than just cells but spirit is circulated. Nordic people often allude to their Viking blood making them hardier and stoic; the ancient Mayans believed blood was given by the Gods to bestow them with life, and frequently gave ritualistic blood-letting ceremonies to return it to them.
Professors Irv Weissman and Ravi Majeti at Stanford University and Professor Paresh Vyas at the MRC Molecular Haematology Unit in Oxford, are working on an antibody from the Stanford investigators that enables the immune system to detect and kill cancer cells. They are now testing whether it’s safe and effective for use in people with blood cancer. In this week’s blog they tell us how they collaborated across the Atlantic to get public funding for a project that has led to a spin out with multiple backers and a promising clinical trial.
What if we could make our immune system fight cancer like it fights infection?
These aren’t the only teams in the world grappling with that question but for Professor Irv Weissman and Professor Paresh Vyas, the solution feels tantalisingly close for patients with blood cancer. Read more